Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

As global markets navigate a turbulent start to 2025, with U.S. stocks experiencing volatility due to AI competition fears and mixed corporate earnings, investors are keenly observing the Federal ...